Biogen Inc.

SNSE:BIIBCL Stock Report

Market Cap: CL$22.8t

Biogen Valuation

Is BIIBCL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIIBCL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIIBCL (CLP155330) is trading below our estimate of fair value (CLP608669.4)

Significantly Below Fair Value: BIIBCL is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIBCL?

Key metric: As BIIBCL is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIIBCL. This is calculated by dividing BIIBCL's market cap by their current earnings.
What is BIIBCL's PE Ratio?
PE Ratio14.4x
EarningsUS$1.62b
Market CapUS$23.29b

Price to Earnings Ratio vs Peers

How does BIIBCL's PE Ratio compare to its peers?

The above table shows the PE ratio for BIIBCL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average79.8x
A068270 Celltrion
204.6x73.8%₩36.7t
UTHR United Therapeutics
15.2x8.1%US$16.8b
HZNP Horizon Therapeutics
60.8x16.4%US$26.6b
BMRN BioMarin Pharmaceutical
38.7x27.2%US$12.4b
BIIBCL Biogen
14.4x12.4%CL$23.3b

Price-To-Earnings vs Peers: BIIBCL is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (86.2x).

Price to Earnings Ratio vs Industry

How does BIIBCL's PE Ratio compare vs other companies in the Global Biotechs Industry?

19 CompaniesPrice / EarningsEstimated GrowthMarket Cap
BIIBCL 14.4xIndustry Avg. 26.1xNo. of Companies19PE020406080100+
19 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIIBCL is good value based on its Price-To-Earnings Ratio (14.4x) compared to the Global Biotechs industry average (26.1x).

Price to Earnings Ratio vs Fair Ratio

What is BIIBCL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIBCL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.4x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate BIIBCL's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIIBCL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCL$155,330.00
CL$248,180.69
+59.8%
18.8%CL$337,222.26CL$177,485.40n/a29
Nov ’25CL$261,090.00
CL$245,673.58
-5.9%
17.1%CL$328,593.60CL$172,944.00n/a29
Oct ’25CL$261,090.00
CL$244,311.80
-6.4%
13.7%CL$309,246.66CL$171,803.70n/a30
Sep ’25CL$261,090.00
CL$256,514.56
-1.8%
13.0%CL$323,217.36CL$179,565.20n/a30
Aug ’25CL$261,090.00
CL$265,170.94
+1.6%
13.6%CL$333,343.50CL$190,482.00n/a30
Jul ’25CL$261,090.00
CL$266,620.95
+2.1%
14.4%CL$329,563.50CL$188,322.00n/a30
Jun ’25CL$261,090.00
CL$259,588.67
-0.6%
14.2%CL$319,039.00CL$182,308.00n/a29
May ’25CL$261,090.00
CL$274,843.09
+5.3%
13.4%CL$336,133.00CL$192,076.00n/a31
Apr ’25CL$261,090.00
CL$294,517.43
+12.8%
12.7%CL$392,080.00CL$225,446.00n/a30
Mar ’25CL$261,090.00
CL$294,517.43
+12.8%
12.7%CL$392,080.00CL$225,446.00n/a30
Feb ’25CL$261,090.00
CL$291,099.39
+11.5%
11.1%CL$377,592.18CL$227,857.35n/a30
Jan ’25CL$261,090.00
CL$278,613.38
+6.7%
10.2%CL$351,152.50CL$213,008.75n/a31
Dec ’24CL$261,090.00
CL$290,699.80
+11.3%
11.1%CL$359,788.98CL$218,247.63n/a29
Nov ’24CL$261,090.00
CL$302,853.76
+16.0%
9.2%CL$373,500.00CL$248,377.50CL$261,090.0029
Oct ’24CL$261,090.00
CL$286,247.05
+9.6%
10.5%CL$381,064.00CL$235,106.00CL$261,090.0029
Sep ’24CL$261,090.00
CL$279,827.49
+7.2%
10.2%CL$374,292.92CL$230,928.43CL$261,090.0028
Aug ’24CL$261,090.00
CL$281,191.50
+7.7%
9.7%CL$365,738.60CL$231,522.60CL$261,090.0028
Jul ’24CL$261,090.00
CL$270,304.37
+3.5%
8.5%CL$319,864.64CL$211,367.84CL$261,090.0027
Jun ’24CL$261,090.00
CL$268,426.90
+2.8%
8.4%CL$319,613.90CL$211,202.15CL$261,090.0027
May ’24CL$261,090.00
CL$265,726.81
+1.8%
8.8%CL$320,987.00CL$212,109.50CL$261,090.0027
Apr ’24CL$261,090.00
CL$265,659.38
+1.8%
9.7%CL$319,615.00CL$205,113.75CL$261,090.0026
Mar ’24CL$261,090.00
CL$266,668.91
+2.1%
9.6%CL$321,135.96CL$206,089.83CL$261,090.0026
Feb ’24CL$261,090.00
CL$261,381.54
+0.1%
10.1%CL$324,615.00CL$201,067.50CL$261,090.0026
Jan ’24CL$261,090.00
CL$283,986.86
+8.8%
8.9%CL$328,005.00CL$218,965.50CL$261,090.0026
Dec ’23CL$261,090.00
CL$280,933.91
+7.6%
9.3%CL$325,455.70CL$217,263.67CL$261,090.0026
Nov ’23n/a
CL$288,789.76
0%
12.0%CL$350,467.70CL$206,491.78CL$261,090.0026

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

Gilead Sciences

US$115.2b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD

US$89.71

7D

0%

1Y

36.9%

Pfizer

US$146.4b

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally.

PFE

US$27.95

7D

0%

1Y

-6.2%

Amgen

US$150.5b

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.

AMGNCL

US$305,690.00

7D

0%

1Y

n/a